Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
01/06/2026 06:00 AM • Apogee Therapeutics reported positive interim Phase 1b results for zumilokibart (APG777), its anti-IL-13 antibody, in mild-to-moderate asthma patients, demonstrating rapid and durable suppression of FeNO biomarker through 16 weeks with a favorable safety profile. The company also highlighted multiple anticipated 2026 milestones including Phase 2 APEX data readouts in atopic dermatitis and potential Phase 3 initiation by late 2026, with a strong cash position of $913 million supporting operations into H2 2028.
APGE - Company announced positive interim Phase 1b clinical trial results showing favorable safety profile and robust FeNO suppression in asthma patients. Multiple clinical readouts are anticipated in 2026, the company has strong cash position of $913 million with runway into H2 2028, and there is potential for Phase 3 initiation and 2029 launch of lead candidate. The expansion of zumilokibart beyond dermatology into respiratory indications demonstrates pipeline diversification and validates the 'pipeline-in-a-product' strategy.
Investing.com • Michael Kramer